

Lars Holmqvist to be proposed to the upcoming Annual General Meeting as a new member of the Board of Tecan

Männedorf, Switzerland, March 18, 2015 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that its Board of Directors will propose the election of Lars Holmqvist as a new member of the Board at the Annual General Meeting.

Lars Holmqvist brings more than 25 years' experience within the medical device, pharmaceutical and life science industries, where he has held roles with increasing responsibilities in marketing, sales and business management. Most recently, he was President of the Life Sciences and Diagnostics Group and Senior Vice President at Agilent Technologies Inc. (NYSE: A).

Lars Holmqvist joined Agilent in June 2012, when Agilent acquired Dako where he had been President and CEO since 2009. Before joining Dako, he served as President, Europe, for Applied Biosystems, where he was later promoted to President, International, with responsibilities for all commercial operations outside the U.S.

The Board will also propose the reelection of current members Rolf A. Classon, Heinrich Fischer, Dr. Oliver S. Fetzer, Gérard Vaillant, Dr. Christa Kreuzburg and Dr. Karen Huebscher for a further one-year term.

After serving on Tecan's Board of Directors for four years, Erik Walldén will not seek reelection at this year's Annual General Meeting.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group

Martin Braendle
Vice President, Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com